<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166490</url>
  </required_header>
  <id_info>
    <org_study_id>ASG5ME-002</org_study_id>
    <nct_id>NCT01166490</nct_id>
  </id_info>
  <brief_title>A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma</brief_title>
  <official_title>A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agensys, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and
      tolerability of ASG-5ME and identify the maximum tolerated dose in patients with
      pathologically confirmed metastatic pancreatic adenocarcinoma, and to evaluate safety and
      tolerability in patients with relapsed or refractory gastric adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events and laboratory abnormalities</measure>
    <time_frame>Through 1 month after last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best clinical response</measure>
    <time_frame>Every 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and progression-free survival</measure>
    <time_frame>Every month until death or study closure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of ASG-5ME and metabolites in blood</measure>
    <time_frame>Through 1 month after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies in blood</measure>
    <time_frame>Through 1 month after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Gastric Neoplasms</condition>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASG-5ME</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASG-5ME</intervention_name>
    <description>0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed metastatic pancreatic adenocarcinoma or pathologically
             confirmed AGS-5-positive gastric or gastric esophageal junction adenocarcinoma

          -  Measurable disease (at least one nonresectable, non-nodal lesion greater than or equal
             to 10 mm in longest diameter or nodal lesion greater than or equal to 15 mm in
             shortest axis)

          -  ECOG performance status of 0 or 1

          -  May be untreated or have previously received treatment for pancreatic adenocarcinoma
             or must have relapsed or refractory disease following 1 prior systemic therapy for
             metastatic gastric adenocarcinoma. For patients who have previously received
             treatment, it must be at least 2 weeks since the last systemic therapy or radiation,
             and at least 4 weeks since treatment with any monoclonal antibody (other than
             bevacizumab).

        Exclusion Criteria:

          -  Evidence or history of central nervous system metastases

          -  History of another primary malignancy that has not been in remission for at least 3
             years

          -  Documented history of a cerebral vascular event, unstable angina, myocardial
             infarction, or cardiac symptoms consistent with NYHA Class III-IV within 6 months
             prior
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Whiting, PharmD, BCOP</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TGen Clinical Research Service at Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2010</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monomethyl auristatin E (MMAE)</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>AGS-5 Antigen</keyword>
  <keyword>SLC44A4 Antigen</keyword>
  <keyword>Gastric Neoplasms</keyword>
  <keyword>Pancreatic Neoplasms</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

